Pulmonary complications occur in 40-60% of bone marrow transplantation (BMT) recipients, accounting for 10-40% of all transplant-related deaths.
Introduction
Pulmonary complications occur in 40-60% of bone marrow transplantation (BMT) recipients, accounting for 10-40% of all transplant-related deaths. 1 Pulmonary function testing following BMT is useful for predicting survival. 2 Indeed, several reports have noted that small airway obstruction with decreased forced expiratory volume in 1 second (FEV 1 ) and FEV 1 /forced vital capacity (FVC) ratio is associated with increased mortality in patients who have received allogeneic BMT. 1 Airflow obstruction has also been correlated with the occurrence of chronic graft-versus-host disease (GVHD) following BMT. [3] [4] [5] Decrease in diffusion capacity of carbon monoxide (DLCO) after BMT has been observed in chronic myelogenous leukemia patients. 6, 7 The mechanisms underlying this deterioration remain unclear. The majority of studies assessing the relationship between pulmonary function and long-term survival following BMT have involved non-homogeneous study populations. To our knowledge, a homogeneous acute lymphoblastic leukemia (ALL) population has not been examined in this manner. Therefore, the aim of this study was to determine whether changes in FEV 1 , DLCO, and the occurrence of chronic GVHD have any longterm prognostic significance in patients with ALL after allogeneic BMT.
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Methods
Patient population
The case records of 55 ALL patients who received allogeneic BMT between August 1983 and February 2005 at our bone marrow unit were retrospectively reviewed. Our investigation was limited to long-term survivors only (defined as surviving for at least 100 days after BMT). 1 Hence, 16 patients who died before 100 days post transplantation and 7 who accepted transplantation before complete remission were excluded. The remaining 32 patients were analyzed.
Twenty-eight patients in the study population accepted induction chemotherapy with OPDL regimen 8 (every 4 weeks with vincristine 1.3 mg/m 2 on day 1, danuomycin 50 mg/m 2 qd on day 1-3, prednisolone 40 mg/m 2 qd till remission) followed by consolidation with cytarabine 1,000 mg/m 2 q12h on day 1-4 and novantrone 6 mg/m 2 qd on day 1-4. Four patients with ALL accepted the hyper-CVAD regimen (cyclophosphamide 300 mg/m 2 bid on day 1-3, vincristine 2 mg on day 4 and day 11, doxorubicin 50 mg/m 2 on day 4, dexamethasone 40 mg on day 1-4 and day 11-14 during courses 1, 3, 5 and 7, and methotrexate 1,000 mg/ m 2 on day 1, cytarabine 3,000 mg/m 2 bid on day 2, day 3 during courses 2, 4, 6 and 8). Intrathecal CNS prophylaxis was performed for 6-8 courses with methotrexate 15 mg, cytarabine 45 mg, and decadron 5 mg in each cycle to all patients according to the situation.
BMT procedure
The treatment regimen included conditioning therapy, GVHD prophylaxis, protective isolation, antibiotics, and supportive care. Patients entered isolation units before initiation of conditioning. The conditioning regimen consisted of total body irradiation (TBI) 150 cGy twice daily for 4 days (total dose 1,200 cGy), with isolating transporter to the radiation room, intravenous cyclophosphamide 60 mg/kg once daily on days 1 and 2 (total dose 120 mg/kg), and intravenous mesna 20 mg/kg 7 times daily (total dose 140 mg/kg) following the cyclophosphamide course. Non-TBI conditioning was as follows: busulfan 4 mg/kg per os in divided doses daily for 4 days (total dose 16 mg/kg), cyclophosphamide 50 mg/kg daily for 4 days (total dose 200 mg/kg), intravenous mesna 20 mg/kg 7 times daily (total dose 140 mg/kg). Most patients received a combination of radiation therapy and chemotherapy.
Patients not allergic to sulfamethoxazole and trimethoprim received prophylactic treatment for 2 weeks before transplantation and from the time of primary discharge after transplantation for at least 6 months, or until peripheral white blood cell counts normalized. 2 Cytomegalovirus (CMV) infection was monitored with CMV-PCR weekly post transplant until 100 days after the day of transfusion. Diagnosis of CMV colitis was confirmed by histologic examination of colonoscopy biopsy specimens. Diagnosis of CMV pneumonitis was confirmed by histologic examination of pulmonary macrophages obtained by broncholavage.
GVHD prophylaxis, grading and treatment
All patients received the following GVHD prophylaxis: intravenous cyclosporin A 5 mg/kg or 6.25 mg/kg per os from day −1 to day +60; intravenous methotrexate 15 mg/m 2 on day +1, and 10 mg/m 2 on days +3, +6 and +11. Acute GVHD was graded according to published criteria. 9 Chronic GVHD was classified as described by Schulman and colleagues. 10 Acute GVHD was treated with prednisolone 2 mg/ kg daily and cyclosporin 6.25 mg/kg daily, adjusted with methylprednisolone at a dose of 20 mg/kg/day for 3-5 days and ATG 30 mg/kg every other day for 6 doses. These doses were increased if improvements were not apparent.
Pulmonary function tests
Pulmonary function tests were performed before, and every 3 months after BMT according to American Thoracic Society guidelines. Measurements were made using the following equipment: between 1983 and 1993, a wet-spirometer (model 750; Med Science Electronics, St Louis, MO, USA) combined with an XY recorder (Hewlett-Packard, Palo Alto, CA, USA) and a 1-second timer; between March 1993 and November 2003, a Sensormedics Autobox 6200 (Sensormedics Co., Yorba Linda, CA, USA); and from December 2003 onwards, a Sensormedics Vmax (Sensormedics Co.). Previously published equations were used to determine predicted FEV 1 values.
11 DLCO was measured using the single-breath technique and corrected for hemoglobin content. Obstruction was categorized as mild (≥ 70% FEV 1 ), moderate (60-69% FEV 1 ), moderately severe (50-59% FEV 1 ), severe (35-49% FEV 1 ), or very severe (< 35%). Diffusion capacity was categorized as pathological (DLCO < 80% of predicted value), mild (60-80% of predicted value), moderate (40-59% of predicted value), or severe (DLCO < 40% of predicted value) according to European Respiratory Society guidelines. Decreases in FEV 1 or DLCO were defined according to the grading systems of the American Thoracic and European Respiratory Societies (ATS/ ERS), 12 and were indicated by an increase of at least 1 severity grade between pre-BMT and 12 months post-BMT (e.g. a shift from mild to moderate, moderate to severe, etc.).
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Statistical methods
Overall and event-free survivals were defined as the intervals between diagnosis and death, and between complete remission and disease recurrence, respectively. The Kaplan-Meier method was used to estimate overall survival and event-free survival. Log-rank tests were performed to assess any association between survival and risk factors. A Cox proportional hazard model was then applied to identify prognostic factors that significantly influenced overall survival and event-free survival. All analyses were performed using the SAS 9.01 statistical software package (SAS Institute Inc., Cary, NC, USA). A p value of less than 0.05 was considered to indicate significance.
Results
Patient characteristics and clinical features
The demographic and clinical characteristics of the 32 ALL patients who survived at least 100 days after allogeneic BMT are presented in Table 1 .
Pulmonary function, chronic GVHD, and prognosis
The univariate analysis results for overall and eventfree survival prognostic factors are presented in Table 2 . Both decreased DLCO and a pre-BMT FEV 1 < 70% significantly influenced overall survival (both p < 0.05). Overall survival was significantly higher in patients with decreased DLCO. Mortality risk was almost 5 times higher when pre-BMT FEV 1 was < 70% of the predicted value. Neither a decreased FEV 1 score post-BMT, nor development of either acute or chronic GVHD influenced overall survival (all p > 0.05). Decreased DLCO after BMT was associated with significantly improved event-free survival (p < 0.05). There were only 6 patients in whom FEV 1 decreased following BMT (relapse was not apparent in any of these individuals); hence, we were unable to establish an association using the Cox proportional model.
Considering the predisposing factors that may influence prognosis, although no apparent significance in univariate analysis was observed in the present study, these factors were enrolled into the multivariate analysis. Multivariate analysis (Table 3) revealed that limited chronic GVHD was associated with a significantly decreased risk of death (HR, 0.14; p < 0.05), while CMV infection significantly increased risk of death (HR, 21.91; p < 0.05). After adjusting for age, gender, chronic GVHD and CMV infection status, decreased DLCO was significantly predictive for both increased overall survival and event-free survival (p < 0.05). Figure 1 shows the Kaplan-Meier overall and eventfree survival curves for patients in whom DLCO did or did not decrease following BMT. The 2-year survival rates were 93% and 64% for patients who did and did not exhibit decreased DLCO scores, respectively. Corresponding 2-year event-free survival rates were 93% and 53%. Both the differences for overall and event-free survivals between the groups were significant (p < 0.05).
Discussion
This study primarily assessed measures of pulmonary function as indicators of long-term outcome in patients with ALL following BMT. Our findings suggest that post-BMT DLCO may be such a prognostic factor.
Previous studies have reported that DLCO decreases are apparent in up to 80% of all BMT survivors, including those in good health. [13] [14] [15] [16] [17] [18] Further to this, it is indicated that DLCO decreases occur within the first 3 months post BMT and that subsequent recovery is incomplete. 2, [19] [20] [21] [22] [23] Such persistent decreases in DLCO may be reflective of permanent damage to the alveolar-endothelial membrane and subclinical pulmonary fibrosis. 6, 24, 25 In the current study, we also found that decreased DLCO 1 year after BMT was associated with enhanced survival rate. A number of previous studies have failed to find such an association between decreased DLCO and mortality. 2, 5, 6, 26 The mechanism(s) underlying the apparent positive influence of decreased DLCO on survival in this study are unclear. Similar interesting findings were observed in a previous study. 27 In Philadelphia chromosome positive (Ph+) ALL patients after allogeneic stem cell transplantation, those with chronic GVHD had better survival compared to those without chronic GVHD. Although the true mechanism of such a clinical finding is unclear, there may be some correlation between chronic GVHD, enhanced graft-versus-leukemia (GVL) effect and decreased DLCO in ALL patients, which warrants further investigation. Several reports have noted an association between diminished FEV 1 due to small airway obstruction and concomitant chronic GVHD and increased frequency of late non-relapse death. 5, 26 We did not find any such associations in the present study. However, as already noted, there was an insufficient number of patients who experienced post-BMT decreases in FEV 1 to allow for definitive analysis. We did find that pre-BMT FEV 1 < 70% was associated with an increased mortality risk. There have been reports indicating that there is an association between abnormal FEV 1 values and an increased risk of treatment-related mortality and posttransplantation CMV infection. 28 A number of studies have indicated that chronic GVHD is a highly significant risk factor for the development of airflow obstruction following BMT. 29, 30 Similarly, others have noted that chronic GVHD is a risk factor for airflow obstruction and increased non-relapse mortality and morbidity after allogeneic BMT. 4, 18, 31 In the current investigation, we found that patients who experienced limited chronic GVHD following allogeneic BMT had better overall survival as compared to patients who did not have GVHD. Yanada and colleagues found that extensive chronic GVHD was associated with increased survival in ALL patients who received allogeneic BMT. 27 The positive impact of limited chronic GVHD on survival might be explained by an associated GVL effect. 27, 32 Crawford and colleagues have previously presented findings demonstrating that decreased DLCO before transplantation is an independent factor for increased risk of death after BMT. 2, 33 We did not find this to be the case in the present study. Our finding is in keeping with that of Ghalie et al, who also found no association between pre-transplant DLCO and post-transplant pulmonary complications or outcome. 34 CMV infection was correlated with mortality in our study. This may be related to the high mortality rate of documented CMV infection and poorer general condition and immunity of the patients who got CMV infections.
There are a number of limitations to our study. Due to the relatively small sample size, associations between decreased FEV 1 , decreased DLCO, and chronic GVHD could not be determined. Thus, we cannot exclude the possibility that the effects of decreased DLCO and chronic GVHD may overlap. Also related to the small sample size, we were not able to assess the effect of decreased DLCO on more long-term survival (i.e. > 1 year). Another shortcoming is that because the data pertaining to total lung capacity were incomplete and could not be analyzed, its significance as a risk factor could not be evaluated. Previous reports have noted reduced total lung capacity to be associated with an increase in non-relapse mortality following BMT. 2, 18 Studies with larger patient groups and/or animal models are warranted to address these unresolved issues.
To our knowledge, this is the first study to examine the relationship between long-term survival and pulmonary function changes in ALL patients after allogeneic BMT. We found that decreased DLCO following allogeneic BMT was associated with better survival in these patients. The relationship between DLCO decrease, chronic GVHD and the GVL effect needs to be further studied. Additional research utilizing the ATS/ERS grading system to separate positive and negative GVL patients may provide further insight.
